Report: Früherkennungsmonitor 2023 (Germany)

forpolicymakers germanycountry Go back to Germany page

Primary purpose: To analyze and provide an overview of the utilization of cancer early detection services offered by the German statutory health insurance (GKV).

Sponsor, manager or home institution: Wissenschaftliches Institut der AOK (WIdO).

Type of information: The report outlines cancer screening services covered by the German statutory health insurance (GKV), including screenings for cervical, prostate, colorectal, breast, and skin cancers, as well as general health checks and screening for abdominal aortic aneurysms. It tracks usage rates of these screenings from 2019 to 2022, noting the impact of the COVID-19 pandemic on participation. A key focus is colorectal cancer screening, analyzing trends in colonoscopy usage for diagnostic and preventive purposes. The report also discusses changes in cancer mortality and cancer incidence in Germany, highlighting declines in certain cancers due to early detection. Additionally, it addresses challenges like false positives and examines regional differences in screening uptake. Click here to learn more.

Data level: national level.

Cancer areas of interest: C15-C26: Digestive system cancers, C43-C44: Skin cancers/melanoma, C50: Breast cancer, C51-C58: Female genitalia cancer, C60-C63: Male genitalia cancer. Click here to learn more.

Access to information: Click here to access.

Esophagus Stomach Small intestine Large intestine Rectum Anus Liver Gallbladder Bile ducts Pancreas Colon Skin Melanoma Scalp Lips Hands Feet Lobular Vulva Prostate Breast Vagina Testicles Nipple Cervix Penis Areola Uterus Ductal Ovary Fallopian tubes Endometrium dataOwner::Wissenschaftliches Institut der AOK (WIdO) availableVariable::screening availableVariable::diagnosis|cervical availableVariable::medical procedures|preventive availableVariable::number of deaths|cancer mortality availableVariable::cancer incidence availableVariable::check-up examinations|false positives dataLevel::national level hasCancerType::C15-C26: Digestive system cancers hasCancerType::C43-C44: Skin cancers/melanoma hasCancerType::C50: Breast cancer hasCancerType::C51-C58: Female genitalia cancer hasCancerType::C60-C63: Male genitalia cancer isReport hasCancerType::C00-D48: All neoplasms hasCancerType::C00-C97: All cancer types hasCancerType::C00-C14: Mouth/throat cancers hasCancerType::C30-C39: Lung/chest cancers hasCancerType::C40-C41: Bone cancers hasCancerType::C45-C49: Soft tissue cancer hasCancerType::C51-C58: Female genitalia cancers hasCancerType::C64-C68: Urinary system cancers hasCancerType::C69-C72: Eye and brain cancer hasCancerType::C73-C75: Thyroid and other gland cancers hasCancerType::C76-C80: Cancers of unknown or unspecified areas hasCancerType::C81-C96: Cancers of the blood and immune system hasCancerType::C97-C97: Cancers in multiple locations from the start hasCancerType::D00-D09: Early-stage cancers not yet spread hasCancerType::D10-D36: Benign tumour hasCancerType::D37-D48: Growths of uncertain nature hasCancerType::unknown